secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001213900-23-012464
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma fails to regain Nasdaq bid-price compliance by Feb 14; granted extension to Aug 14, 2023
--------------------------------------------------------------------------------

- Company missed initial Feb 14, 2023 deadline to close at $1.00 for 10 consecutive business days.
- Nasdaq granted an additional 180-day compliance period, now expiring August 14, 2023.
- If bid price closes at $1.00 or more for 10 consecutive days before Aug 14, compliance confirmed.
- Failure to regain compliance by Aug 14 could lead to delisting; Company may appeal.
- Common stock continues trading on Nasdaq Capital Market under symbol ABVC in the interim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023012464/0001213900-23-012464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023012464/ea173774-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-012464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer